Active Not RecruitingNCT06922110
An Open-Label Study of Azetukalner in Major Depressive Disorder
Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with depression.
Medication studyAges 18+Multiple countries
Understand this study
What is this study about?
Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Phoenix and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 18, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 460
- Sponsor
- Xenon Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Finland, Poland
- Age range
- Over 18 Years
- Official registry ID
- NCT06922110
- Official title
Show the full official title
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
Recruitment & locations
Not recruitingPhoenix, United States · Bryant, United States · Little Rock, United States
60 more locations
- Rogers, United States
- Bellflower, United States
- Irvine, United States
- Los Angeles, United States
- Oceanside, United States
- Orange, United States
- San Diego, United States
- Sherman Oaks, United States
- Torrance, United States
- Upland, United States
- Walnut Creek, United States
- Cromwell, United States
- Hartford, United States
- Coral Gables, United States
- Coral Springs, United States
- Fort Myers, United States
- Gainesville, United States
- Hialeah, United States
- Jacksonville, United States
- Lakeland, United States
- Largo, United States
- North Miami Beach, United States
- Orlando, United States
- Pensacola, United States
- Riverview, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Savannah, United States
- Chicago, United States
- Orland Park, United States
- Baltimore, United States
- Boston, United States
- Springfield, United States
- Watertown, United States
- Worcester, United States
- O'Fallon, United States
- Saint Charles, United States
- Las Vegas, United States
- Cherry Hill, United States
- Princeton, United States
- Toms River, United States
- Brooklyn, United States
- Mount Kisco, United States
- New York, United States
- Staten Island, United States
- Cary, United States
- Charlotte, United States
- Independence, United States
- Oklahoma City, United States
- Allentown, United States
- Philadelphia, United States
- Memphis, United States
- Austin, United States
- Plano, United States
- Wichita Falls, United States
- Provo, United States
- Everett, United States
- Oulu, Finland
- Poznan, Poland
A listed location does not confirm current availability.
About the molecule
When a study medicine is clearly identified, HopeStage adds a short explanation of what that molecule is and links back to reliable public sources.
Azetukalner
an experimental Kv7 potassium-channel opener
targets Kv7 potassium channels
Questions about this study
What is this study about?
Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with depression.
Who is behind this study?
The study sponsor is Xenon Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including Azetukalner.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
